ArticleCureus2026
Advanced Cirrhosis Is Independently Associated With Increased In-Hospital Mortality in Heart Failure With Reduced Ejection Fraction.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Advanced cirrhosis is associated with systemic hemodynamic changes that may be associated with worse outcomes in patients with heart failure with reduced ejection fraction (HFrEF). However, national‑level estimates of the independent association between advanced cirrhosis and in‑hospital mortality in this population remain limited. Methods We conducted a retrospective cross‑sectional analysis of the 2022 National Inpatient Sample (NIS). Adults hospitalized with a primary diagnosis of HFrEF (ICD 10 I50.22) were included. Advanced cirrhosis was defined as cirrhosis with at least one decompensating feature: ascites, hepatic encephalopathy, portal hypertension, variceal bleeding, or hepatorenal syndrome. The primary outcome was in‑hospital mortality. Multivariable logistic regression was adjusted for demographics, hospital characteristics, and all Elixhauser comorbidities. Results Among 254,571 weighted HFrEF hospitalizations, 5,346 (2.1%) met criteria for advanced cirrhosis. Compared to those without advanced cirrhosis, affected patients were younger (mean age: 58.4 versus 71.2 years; p<0.001) and more frequently male (68.2% versus 54.9%; p<0.001). Unadjusted in‑hospital mortality was higher in the advanced cirrhosis group (9.7% versus 3.8%; p<0.001). After multivariable adjustment, advanced cirrhosis remained independently associated with increased mortality (adjusted odds ratio (aOR): 2.18; 95% confidence interval (CI): 1.79‑2.64; p<0.001). Using a stricter definition requiring two or more decompensating features, the association strengthened (aOR: 2.59; 95% CI: 2.04‑3.29). Conclusion In this nationally representative sample of HFrEF hospitalizations, advanced cirrhosis was independently associated with more than double the odds of in‑hospital death. This association persisted across age and sex subgroups and showed a dose‑response relationship with disease severity. Early recognition and multidisciplinary management involving cardiology, hepatology, and critical care is reasonable to consider. Prospective studies are needed to determine whether specific therapeutic strategies can improve survival in this high‑risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.